Therefore we established an erlotinib-resistant in vitro model system using PC9 NSCLC cells ectopically overexpressing the exon 19 deletion EGFR mutant and identified genes whose expression is significantly increased or decreased in erlotinib-resistant clones compared to parental cell lines by expression profiling. This evidence concerns the gene EGFR and non-small cell lung carcinoma.